Therefore, CD38 is an appealing tumor-associated antigen for targeted therapy; and monoclonal antibodies against CD38, such as daratumumab, have shown efficacy in the clinical treatment of relapsed and refractory multiple myeloma (RRMM) and newly diagnosed MM patients (11–13). The gene discussed is CD38; the disease is Miyoshi myopathy.